SpringWorks Therapeutics Reports First Quarter 2024 Financia

– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – ...

Related Keywords

United States , American , Samantha Hilson Sandler , Saqib Islam , European Medicines Agency , Nasdaq , American Society Of Clinical Oncology , Linkedin , Youtube , Drug Administration , Trademark Office , Springworks Therapeutics Inc , Development Rd Expenses , Beigene Ltd , Twitter , European Union , Works Therapeutics , Chief Executive Officer , Business Highlights , Supplemental New Drug Application , Marketing Authorization Application , Clinical Oncology , Springworks Sponsored Phase , Epidermal Growth Factor Receptor , Beigene Sponsored Phase , Loss Attributable , Common Stockholders , Cash Equivalents , Marketable Securities , Private Securities Litigation Reform Act , Springwork Quarterly Report , Consolidated Statements , Markets ,